1510 related articles for article (PubMed ID: 32430012)
21. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
22. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
[TBL] [Abstract][Full Text] [Related]
23. Stem Cell Responsiveness to Imatinib in Chronic Myeloid Leukemia.
Lahlil R; Aries A; Scrofani M; Zanetti C; Hennequin D; Drénou B
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068992
[TBL] [Abstract][Full Text] [Related]
24. The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities.
Ciftci HI; Ozturk SE; Ali TFS; Radwan MO; Tateishi H; Koga R; Ocak Z; Can M; Otsuka M; Fujita M
Biol Pharm Bull; 2018 Apr; 41(4):570-574. PubMed ID: 29386476
[TBL] [Abstract][Full Text] [Related]
25. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
Bandyopadhyay S; Li J; Traer E; Tyner JW; Zhou A; Oh ST; Cheng JX
PLoS One; 2017; 12(7):e0179558. PubMed ID: 28719608
[TBL] [Abstract][Full Text] [Related]
26. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
27. Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells.
Okabe S; Tanaka Y; Moriyama M; Gotoh A
Cancer Chemother Pharmacol; 2020 Feb; 85(2):401-412. PubMed ID: 31901955
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
29. Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells.
Wang XY; Sun GB; Wang YJ; Yan F
Biol Pharm Bull; 2020; 43(10):1526-1533. PubMed ID: 32999163
[TBL] [Abstract][Full Text] [Related]
30. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
31. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
Borgo C; Cesaro L; Salizzato V; Ruzzene M; Massimino ML; Pinna LA; Donella-Deana A
Mol Oncol; 2013 Dec; 7(6):1103-15. PubMed ID: 24012109
[TBL] [Abstract][Full Text] [Related]
32. HDAC1,2 Knock-Out and HDACi Induced Cell Apoptosis in Imatinib-Resistant K562 Cells.
Chen SH; Chow JM; Hsieh YY; Lin CY; Hsu KW; Hsieh WS; Chi WM; Shabangu BM; Lee CH
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31071955
[TBL] [Abstract][Full Text] [Related]
33. Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.
Mitchell R; Hopcroft LEM; Baquero P; Allan EK; Hewit K; James D; Hamilton G; Mukhopadhyay A; O'Prey J; Hair A; Melo JV; Chan E; Ryan KM; Maguer-Satta V; Druker BJ; Clark RE; Mitra S; Herzyk P; Nicolini FE; Salomoni P; Shanks E; Calabretta B; Holyoake TL; Helgason GV
J Natl Cancer Inst; 2018 May; 110(5):467-478. PubMed ID: 29165716
[TBL] [Abstract][Full Text] [Related]
34. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.
Ng KP; Manjeri A; Lee KL; Huang W; Tan SY; Chuah CT; Poellinger L; Ong ST
Blood; 2014 May; 123(21):3316-26. PubMed ID: 24705490
[TBL] [Abstract][Full Text] [Related]
35. Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia.
Kayabasi C; Okcanoglu TB; Yelken BO; Asik A; Susluer SY; Avci CB; Saydam G; Gunduz C
Gene; 2017 Dec; 637():173-180. PubMed ID: 28942039
[TBL] [Abstract][Full Text] [Related]
36. Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.
Matsuda Y; Yamauchi T; Hosono N; Uzui K; Negoro E; Morinaga K; Nishi R; Yoshida A; Kimura S; Maekawa T; Ueda T
Cancer Sci; 2016 Jul; 107(7):1029-38. PubMed ID: 27166836
[TBL] [Abstract][Full Text] [Related]
37. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
[TBL] [Abstract][Full Text] [Related]
38. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
39. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.
Chen M; Gallipoli P; DeGeer D; Sloma I; Forrest DL; Chan M; Lai D; Jorgensen H; Ringrose A; Wang HM; Lambie K; Nakamoto H; Saw KM; Turhan A; Arlinghaus R; Paul J; Stobo J; Barnett MJ; Eaves A; Eaves CJ; Holyoake TL; Jiang X
J Natl Cancer Inst; 2013 Mar; 105(6):405-23. PubMed ID: 23446755
[TBL] [Abstract][Full Text] [Related]
40. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
Jin B; Wang C; Shen Y; Pan J
Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
